Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

Endo Pharmaceuticals

Status and phase

Terminated

Phase 3

Conditions

Carpal Tunnel Syndrome

Treatments

Drug: lidocaine patch 5%

Study type

Interventional

Funder types

Industry

Identifiers

NCT00266214

EN3272-301

Details and patient eligibility

About

The purpose of this study is to evaluate the analgesic efficacy and safety of the lidocaine patch 5% compared to placebo in patients with moderate to severe pain associated with carpal tunnel syndrome.

Full description

Patients with carpal tunnel syndrome (CTS)as determined by electrodiagnostic testing and moderate to severe pain will be randomized to receive either the lidocaine patch 5% or placebo patch q24h. The total duration of the double-blind treatment phase of the study will be 8 weeks.

At baseline and at periodic visits to the clinic, patients will perform pain and functionality assessments. Patients with bilateral CTS will identify the "index" wrist (i.e., the more painful wrist), which will subsequently be the wrist used for all efficacy assessments throughout the study.

Treatment Regimen and Route of Administration: Patients will apply one patch (either a lidocaine patch 5% or a matching placebo patch) to the volar aspect of each affected wrist once every 24 hours.

Enrollment

210 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Are males or females 18 years of age or older
Have confirmed diagnosis of CTS in one or both wrists. For patients with bilateral CTS, the most painful wrist will be identified as the "index" wrist, and will be the wrist used for all efficacy evaluations.
Have clinical symptoms of pain, paresthesia, numbness and/or tingling in the distribution of the median nerve
Have positive findings from electrodiagnostic tests using accepted criteria
Have classification of the wrist(s) as "classic" or "probable" using the Katz Hand Diagram (Katz and Stirrat, 1990)
Have worst daily pain intensity greater than 5 (0-10 scale) on approximately 75% of days over the previous 3 months; this criteria will be assessed at the screening visit only
Have a normal 12-lead electrocardiogram (ECG) without any clinically significant abnormalities in heart rate, rhythm, or conduction
Have been informed of the nature of the study and provided written informed consent

Exclusion criteria

Have a positive serum pregnancy test (females of childbearing potential only)
Have tumors or cysts in the wrist, muscle wasting in the forearm and/or hand, peripheral neuropathy, mononeuropathy multiplex, or hand arthritis
Have had previous CTS surgery
Have severe CTS as defined by electrodiagnostic findings
Have had steroid injections for CTS in the previous 3 months
Have used diuretics (except a stable dose for hypertension) or Vitamin B6 or topical treatments for CTS (e.g., ultrasound, iontophoresis, cold laser) in the past 2 weeks
Require sleep medications
Are using a lidocaine-containing product that cannot be discontinued during the study
Have a known sensitivity or allergy to an amide-type local anesthetic agent para-aminobenzoic (PABA) derivatives or local anesthetics
Have previously participated in a Lidoderm study
Have severe renal insufficiency (creatinine clearance of <30 mL/min)
Have moderate or greater hepatic impairment, including a history of or active hepatitis
Have abnormal clinical laboratory test results unless deemed clinically insignificant by the investigator
Have current or planned litigation, or who are planning to acquire or are currently receiving Worker's Compensation or Social Security benefits, or who, in the opinion of the investigator, exhibit any evidence of secondary gain (monetary or non-monetary) associated with carpal tunnel syndrome pain.
Have a history of alcohol or substance abuse within the last 3 years
Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days or 5 half-lives prior to receiving study drug